Anlon Healthcare Limited Stock Price Today (NSE: AHCL)

Anlon Healthcare Limited

20.040.14 (0.69%)
Market Closed

Fundamental Score

...

Anlon Healthcare Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Anlon Healthcare Limited share price today is 20.04, down 0.69% on NSE/BSE as of 16 September 2026. Anlon Healthcare Limited (AHCL) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 1.07K (Cr). The 52-week high for AHCL share price is 22.94 and the 52-week low is 10.37. At a P/E ratio of 3.43x, AHCL is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 19.17% and a debt-to-equity ratio of 0.19.

Anlon Healthcare Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
20.04
Low
14.10
Volume
38.2L
Change
+12.66%

Anlon Healthcare Limited share price chart: 12.66% return over the past month. 52-week high ₹22.94, 52-week low ₹10.37.

Anlon Healthcare Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
20.2020.5019.6020.04460.66L (Cr)
21.0522.9419.3720.181650.56L (Cr)
17.7320.0017.5419.571507.49L (Cr)
16.4118.0016.0517.54316.30L (Cr)
15.6216.6815.6216.28174.59L (Cr)
15.5415.6915.4115.6114.55L (Cr)
15.7415.8515.4115.5121.77L (Cr)
15.6815.8915.5415.6820.50L (Cr)
15.4716.2515.4715.6051.13L (Cr)
15.4915.7615.3215.5616.68L (Cr)

Anlon Healthcare Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
15.9322.9415.3220.04+25.80%
14.4516.8713.8115.86+9.76%
16.0016.4514.1814.61-8.69%
13.9816.7813.4515.99+14.38%
13.3015.0212.9913.85+4.14%
11.4917.2011.1013.30+15.71%
10.6713.3010.3711.14+4.40%
12.1013.2010.6310.85-10.31%
15.1816.1012.1512.24-19.37%
17.0017.2413.3015.10-11.18%
12.8017.2712.8016.86+31.73%
13.3513.4511.9112.86-3.66%

Returns & Performance

Good

Return on Equity (ROE)

19.17%

Profit generated per ₹1 of shareholder equity

Excellent

Return on Capital (ROCE)

22.38%

Returns generated on total capital deployed

Excellent

Oper. Profit Margin (5Y Avg)

21.10%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Anlon Healthcare Limited Valuation Check

Excellent

Price to Earnings (P/E)

3.43x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

52.68%

% shares held by company founders/management

Poor

FII Holding

0.32%

% shares held by foreign institutional investors

Poor

DII Holding

4.60%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-100.00%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

162.97%

Revenue growth vs same quarter last year

Excellent

Revenue Growth (5-Year CAGR)

61.67%

Compounded annual revenue growth over 5 years

Excellent

EPS Growth (5-Year CAGR)

21.19%

Earnings per share growth over 5 years

Excellent

Net Profit Growth (5-Year CAGR)

36.40%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.19x

Total debt ÷ equity. Below 0.5 = financially healthy

Excellent

Interest Coverage Ratio

12.36x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-97.24 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Anlon Healthcare Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of AHCL across key market metrics for learning purposes.

Positive Indicators

13 factors identified

Strong Return on Equity (19.17%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (22.38%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.

Strong Operating Margins (21.10%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages.

Attractive Valuation (P/E: 3.43 vs Industry: 34.89)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity.

Strong Revenue Growth (162.97%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Consistent Growth Track Record (61.67% CAGR)

Observation: Strong 5-year sales compound annual growth rate.

Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.

Excellent EPS Growth (21.19% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential.

Strong Profit Growth Track Record (36.40% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model.

Conservative Debt Levels (D/E: 0.19)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Strong Interest Coverage (12.36x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk.

Healthy Liquidity Position (Current Ratio: 2.87)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (52.68%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

4 factors identified

Profit Decline Concern (-100.00%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Negative Free Cash Flow (₹-97.24 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 4.92%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Anlon Healthcare Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Anlon Healthcare Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
60.3/100
20
₹1065.16
3.4
Average
19.17%
Good
22.38%
Excellent
0.2
Excellent
36.40%
Excellent
61.67%
Excellent
0.00%
66.4/100
1865
₹447445.46
37.0
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9488
₹251432.00
86.1
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4930
₹166860.78
78.8
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1127
₹112514.52
25.1
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1363
₹110118.03
32.7
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1937
₹104646.43
95.6
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1699
₹97754.71
26.5
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96022.50
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1145
₹95607.50
29.6
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2265
₹93544.50
45.8
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Anlon Healthcare Limited Quarterly Performance

Latest quarterly metrics for AHCL — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

162.97%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-100.00%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

61.67%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

36.40%

Compounded annual net profit growth over 5 years

Anlon Healthcare Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for AHCL — calculated from daily price history

74RSI 14
Overbought — RSI 74

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
15
▲ Price above SMA 50 — Short-term bullish
SMA 200
14
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
4230K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Anlon Healthcare Limited Financial Statements

Annual income statement, balance sheet and cash flow for Anlon Healthcare Limited (AHCL) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Anlon Healthcare Limited

Loading latest quarterly results...

About AHCL (Anlon Healthcare Limited)

Anlon Healthcare is a multifaceted pharmaceutical entity, dedicated to the synthesis and distribution of sophisticated pharmaceutical components across the globe. The company speci...alizes in crafting meticulously engineered intermediates, the crucial building blocks that underpin the creation of final drug formulations. These components are designed to meet the rigorous demands of modern pharmaceutical manufacturing, ensuring both efficacy and safety in the end products. Anlon Healthcare operates with a commitment to precision and innovation, constantly seeking to improve its processes and product offerings to stay at the forefront of the ever-evolving pharmaceutical landscape. Their commitment to quality extends to all stages of their operations, from research and development to manufacturing and distribution. The company's expansive portfolio encompasses a wide array of specialized pharmaceutical ingredients, catering to diverse therapeutic areas. Anlon Healthcare produces active pharmaceutical ingredients (APIs), the very core of medicinal action, as well as nutraceutical APIs for health and wellness applications. They also develop ingredients tailored for personal care products, contributing to advancements in skincare and cosmetic formulations. Further extending their reach, Anlon Healthcare provides veterinary APIs, ensuring the health and well-being of animals. This diversity reflects the company's ability to adapt and innovate, meeting the varying needs of both human and animal healthcare sectors with tailored solutions. By serving various sectors, Anlon is contributing to innovation of healthcare. Anlon Healthcare's products serve as essential components in numerous therapeutic categories, contributing to advancements in treatment and management. These include drugs used in addressing inflammation, pain relief, and fever reduction, as well as antihistamines, antidepressants, and antipsychotics for mental health applications. Their ingredients are also vital in the production of anticoagulants, antihypertensives, and medications for managing conditions such as arrhythmia, hyperparathyroidism, and diabetes. By consistently producing high-quality intermediates and APIs, Anlon Healthcare contributes to the continuous development of novel therapeutic solutions and the improvement of patient outcomes globally. By focusing on innovation, Anlon is constantly adapting to the change in pharmaceutical needs.

Company Details

Symbol:AHCL
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Punitkumar Rameshbhai Rasadia
Chairman & MD
Mr. Hiteshkumar Bavanjibhai Makwana
Chief Financial Officer
Ms. Amitabhen Chhaganbhai Pragada
Company Secretary & Compliance Officer

AHCL Share Price: Frequently Asked Questions

What is the current share price of Anlon Healthcare Limited?

Anlon Healthcare Limited (AHCL) trades at ₹20.04 on NSE and BSE. Market cap ₹1.07K (Cr). Educational data only.

What is the P/E ratio of Anlon Healthcare Limited?

Anlon Healthcare Limited has a P/E of 3.43x vs industry average 34.89x.

What is the Bull Run score for Anlon Healthcare Limited?

Anlon Healthcare Limited has a Bull Run score of 60.3/100 based on 25+ financial parameters.

Does Anlon Healthcare Limited pay dividends?

Anlon Healthcare Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Anlon Healthcare Limited?

Anlon Healthcare Limited has ROE of 19.17%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Anlon Healthcare Limited?

Anlon Healthcare Limited has debt-to-equity of 0.19.

Is Anlon Healthcare Limited a good investment?

Bull Run gives Anlon Healthcare Limited a score of 60.3/100. This is not investment advice — consult a SEBI-registered advisor.